Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $53.00 price target on Insmed (NASDAQ: INSM), following the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE